Abstract
Objective: To determine the extent to which disease duration, alone or in combination with other baseline clinical and non-clinical factors, explains variations in outcome of tocilizumab initiated in biologic-naïve patients with established RA. Methods: In this pooled analysis of phase 3 and 4 clinical trials conducted by the sponsor, predictors
... read more